Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from RaQualia Pharma Inc. ( (JP:4579) ).
RaQualia Pharma reported first-quarter 2026 consolidated net sales of ¥801 million, down 16.9% year on year, and swung to an operating loss of ¥160 million and a net loss of ¥225 million, reflecting weaker sales and higher costs. Despite the loss, its financial position strengthened with total assets rising to ¥11.39 billion, equity ratio improving to 70.5%, and additional shares issued, while it maintained a no-dividend policy and forecast full-year 2026 net sales of ¥3.98 billion with a smaller full-year net loss, indicating expectations of improved performance later in the year.
The company also recorded a change in consolidation scope with the exclusion of TMRC Co., Ltd., and applied special accounting treatments for its quarterly statements. Management continues to provide annual rather than semiannual forecasts and plans to brief investors via a live webcast, underscoring an emphasis on transparency as it navigates near-term losses and aims for operational recovery.
More about RaQualia Pharma Inc.
RaQualia Pharma Inc., listed on the Tokyo Stock Exchange, operates in the pharmaceutical industry, focusing on drug discovery and related research and development activities. The company generates revenue from licensing and collaboration deals as well as development-driven milestones, positioning it as an R&D-oriented player rather than a mass-market drug manufacturer.
Average Trading Volume: 260,644
Technical Sentiment Signal: Hold
Current Market Cap: Yen18.1B
Find detailed analytics on 4579 stock on TipRanks’ Stock Analysis page.